BriaCell closes spinout of BriaPro to shareholders; retains 66.6% stake

BriaCell Therapeutics Corp.

Closed plan of arrangement spinning out Bria-TILsRx™ and PKCδ inhibitors to BriaPro.
Shareholders receive one BriaPro share and one new BriaCell share per existing share.
BriaCell now owns ~66.6% (31,963,452 shares) of BriaPro's outstanding shares.
BriaPro becomes unlisted reporting issuer in Canada; BriaCell remains on Nasdaq and TSX.
New BriaCell common shares expected to trade on or about Sept 5, 2023 under 'BCT'.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.